JP2013520999A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013520999A5 JP2013520999A5 JP2012556250A JP2012556250A JP2013520999A5 JP 2013520999 A5 JP2013520999 A5 JP 2013520999A5 JP 2012556250 A JP2012556250 A JP 2012556250A JP 2012556250 A JP2012556250 A JP 2012556250A JP 2013520999 A5 JP2013520999 A5 JP 2013520999A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antibody fragment
- seq
- disease
- der
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31045010P | 2010-03-04 | 2010-03-04 | |
| US61/310,450 | 2010-03-04 | ||
| PCT/US2011/027094 WO2011109662A1 (en) | 2010-03-04 | 2011-03-03 | Monoclonal antibodies directed to cd52 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016130517A Division JP2017000142A (ja) | 2010-03-04 | 2016-06-30 | Ｃｄ５２に対するモノクローナル抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013520999A JP2013520999A (ja) | 2013-06-10 |
| JP2013520999A5 true JP2013520999A5 (https=) | 2014-04-17 |
Family
ID=44531535
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012556250A Pending JP2013520999A (ja) | 2010-03-04 | 2011-03-03 | Ｃｄ５２に対するモノクローナル抗体 |
| JP2016130517A Pending JP2017000142A (ja) | 2010-03-04 | 2016-06-30 | Ｃｄ５２に対するモノクローナル抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016130517A Pending JP2017000142A (ja) | 2010-03-04 | 2016-06-30 | Ｃｄ５２に対するモノクローナル抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US8652470B2 (https=) |
| EP (1) | EP2542258A4 (https=) |
| JP (2) | JP2013520999A (https=) |
| AU (2) | AU2011223547B2 (https=) |
| BR (1) | BR112012022342A2 (https=) |
| CA (1) | CA2791866A1 (https=) |
| WO (1) | WO2011109662A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010110838A2 (en) | 2009-03-25 | 2010-09-30 | Vet Therapeutics Inc. | Antibody constant domain regions and uses thereof |
| US9616120B2 (en) | 2010-03-04 | 2017-04-11 | Vet Therapeutics, Inc. | Monoclonal antibodies directed to CD20 |
| BR112012022342A2 (pt) | 2010-03-04 | 2017-02-14 | Vet Therapeutics Inc | anticorpos monoclonais dirigidos a cd52 |
| ES2704007T3 (es) * | 2011-05-06 | 2019-03-13 | Nexvet Australia Pty Ltd | Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos |
| CA2853637C (en) | 2011-10-26 | 2023-04-04 | Novartis Ag | Anti-canine cd20 monoclonal antibodies and methods of use |
| EP2750690B1 (en) | 2011-11-15 | 2018-11-07 | The Walter and Eliza Hall Institute of Medical Research | Soluble mediator |
| AU2013344807B2 (en) * | 2012-11-15 | 2018-05-24 | The Walter And Eliza Hall Institute Of Medical Research | Soluble mediator |
| AU2014240083C1 (en) * | 2013-03-15 | 2019-10-24 | Celgene Corporation | Modified T lymphocytes |
| JP6701079B2 (ja) | 2013-12-20 | 2020-05-27 | インターベット インターナショナル ベー． フェー． | ヒトｐｄ−１に対するイヌ化マウス抗体 |
| ES3063961T3 (en) | 2014-02-14 | 2026-04-21 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| US10550194B2 (en) | 2014-09-30 | 2020-02-04 | Intervet Inc. | PD-L1 antibodies binding canine PD-L1 |
| US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
| WO2017102920A1 (en) | 2015-12-18 | 2017-06-22 | Intervet International B.V. | Caninized human antibodies to human and canine il-4r alpha |
| JP2023545099A (ja) | 2020-10-08 | 2023-10-26 | アフィメド ゲーエムベーハー | 三重特異性バインダー |
| CA3216098A1 (en) | 2021-07-30 | 2023-02-02 | Uwe Reusch | Duplexbodies |
| AU2022382368A1 (en) | 2021-11-03 | 2024-05-02 | Affimed Gmbh | Bispecific cd16a binders |
| CN116785434A (zh) * | 2023-03-29 | 2023-09-22 | 暨南大学附属第一医院（广州华侨医院） | 一种cd52+巨噬细胞作为骨关节炎治疗靶点的应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU640397B2 (en) | 1989-08-25 | 1993-08-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin |
| US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
| DK0580737T3 (da) | 1991-04-10 | 2004-11-01 | Scripps Research Inst | Heterodimere receptorbiblioteker ved anvendelse af phagemider |
| JP3919830B2 (ja) | 1992-11-28 | 2007-05-30 | 財団法人化学及血清療法研究所 | 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片 |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| JP3087696B2 (ja) | 1997-07-25 | 2000-09-11 | 日本電気株式会社 | 分散メモリ型マルチプロセッサ・システム制御方法およびコンピュータ読み取り可能な記録媒体 |
| US6573372B2 (en) | 1999-01-07 | 2003-06-03 | Heska Corporation | Feline immunoglobulin E molecules and compositions there of |
| EP1246607B1 (en) | 1999-12-30 | 2007-06-27 | Dana-Farber Cancer Institute, Inc. | Proteoliposomes containing an integral membrane protein having one or more transmembrane domains |
| WO2001077332A2 (en) | 2000-04-07 | 2001-10-18 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| AU2002359568B2 (en) | 2001-12-03 | 2008-02-21 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
| GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
| EP1485126A4 (en) | 2001-12-21 | 2007-03-21 | Idexx Lab Inc | DOG IMMUNOGLOBULIN VARIABLE DOMAINS, DOG ANTIBODIES, AND METHOD FOR THEIR PRODUCTION AND USE |
| KR101033196B1 (ko) | 2002-02-14 | 2011-05-09 | 이뮤노메딕스, 인코오포레이티드 | 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법 |
| US20040001828A1 (en) * | 2002-02-21 | 2004-01-01 | Joseph Tuscano | Treatment methods using anti-CD22 antibodies |
| ES2263984T3 (es) | 2002-06-28 | 2006-12-16 | Domantis Limited | Ligandos doble-especificos con una vida media serica aumentada. |
| BR0316101A (pt) | 2002-11-07 | 2005-09-27 | Immunogen Inc | Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos |
| WO2005042581A2 (en) * | 2003-11-01 | 2005-05-12 | Biovation Ltd. | Modified anti-cd52 antibody |
| EP1751187A2 (en) * | 2004-05-28 | 2007-02-14 | Idexx Laboratories, Inc. | Canine cd20 compositions |
| EP1778726A4 (en) | 2004-08-16 | 2009-03-18 | Medimmune Inc | INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY |
| EP1810035A4 (en) | 2004-11-10 | 2010-03-17 | Macrogenics Inc | GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION |
| EP3479844B1 (en) | 2005-04-15 | 2023-11-22 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| JP2009504136A (ja) * | 2005-05-24 | 2009-02-05 | アベスタゲン リミテッド | 慢性リンパ性白血病治療のためのｃｄ５２に対するモノクローナル抗体産生のための組み換え法 |
| HUE029465T2 (en) | 2005-08-10 | 2017-02-28 | Macrogenics Inc | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
| GB0707640D0 (en) | 2007-04-20 | 2007-05-30 | Strathclyde | Acoustic deterrence |
| EP2725037A1 (en) * | 2008-09-04 | 2014-04-30 | Vet Therapeutics, Inc. | Monoclonal antibodies binding canine CD20 |
| WO2010110838A2 (en) | 2009-03-25 | 2010-09-30 | Vet Therapeutics Inc. | Antibody constant domain regions and uses thereof |
| BR112012022342A2 (pt) | 2010-03-04 | 2017-02-14 | Vet Therapeutics Inc | anticorpos monoclonais dirigidos a cd52 |
| JP5911813B2 (ja) | 2010-03-04 | 2016-04-27 | ベット・セラピューティクス・インコーポレイテッドＶｅｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | Ｃｄ２０に対するモノクローナル抗体 |
-
2011
- 2011-03-03 BR BR112012022342A patent/BR112012022342A2/pt not_active IP Right Cessation
- 2011-03-03 US US13/040,170 patent/US8652470B2/en active Active
- 2011-03-03 EP EP11751388.7A patent/EP2542258A4/en not_active Withdrawn
- 2011-03-03 JP JP2012556250A patent/JP2013520999A/ja active Pending
- 2011-03-03 WO PCT/US2011/027094 patent/WO2011109662A1/en not_active Ceased
- 2011-03-03 AU AU2011223547A patent/AU2011223547B2/en not_active Ceased
- 2011-03-03 CA CA2791866A patent/CA2791866A1/en not_active Abandoned
-
2014
- 2014-01-17 US US14/158,653 patent/US20140341912A1/en not_active Abandoned
-
2016
- 2016-06-30 JP JP2016130517A patent/JP2017000142A/ja active Pending
- 2016-08-05 AU AU2016210744A patent/AU2016210744A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013520999A5 (https=) | ||
| JP2013520990A5 (https=) | ||
| Cambridge et al. | B cell depletion therapy in systemic lupus erythaematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response | |
| Kortlever et al. | Myc cooperates with Ras by programming inflammation and immune suppression | |
| Piccione et al. | A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells | |
| JP2012121878A5 (https=) | ||
| JP2020511123A5 (https=) | ||
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
| JO3764B1 (ar) | جزيئات إرتباط il-18 | |
| DOP2013000129A (es) | PROTEÍNAS DE UNIÓN AL TNF-a. | |
| JO3097B1 (ar) | الأجسام المضادة c-Met | |
| BR112016014284A2 (pt) | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo | |
| BR112012007365A2 (pt) | proteínas de ligação à il-1 | |
| BR112013028523A2 (pt) | uso de um anticorpo ou uma proteína de fusão ou um fragmento de ligação da mesma e método para a purificação de um anticorpo, uma proteína de fusão ou um fragmento de ligação da mesma de uma mistura fonte | |
| JP2011184466A5 (https=) | ||
| EA201400390A1 (ru) | Антитела к tl1a и их применение | |
| FI3736291T3 (fi) | Anti-fcrh5-vasta-aineita | |
| JP2014061000A5 (https=) | ||
| BRPI0821682A2 (pt) | Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif. | |
| FI3842456T3 (fi) | Monoklonaalinen interleukiini-31-vasta-aine | |
| JP2014503189A5 (https=) | ||
| JP2013538057A5 (https=) | ||
| JP2014523401A5 (https=) | ||
| NZ629178A (en) | Antibodies to matrix metalloproteinase 9 | |
| FI3036258T3 (fi) | Immunoreseptorin modulointi syövän ja virusinfektioiden hoitamiseksi |